Astri Stock Analysis

ATXS -  USA Stock  

USD 4.89  0.06  1.24%

The big decline in price over the last few months for Astri Therapeutics could raise concerns from retail investors as the firm it trading at a share price of 4.89 on 18,500 in volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Astri Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.91. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Astri Therapeutics partners.
Please continue to Trending Equities.

Astri Stock Analysis 

The Astri Therapeutics stock analysis report makes it easy to digest most publicly released information about Astri Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Astri Stock analysis module also helps to analyze the Astri Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Astri Stock Analysis Notes

About 59.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.85. Some equities with similar Price to Book (P/B) outperform the market in the long run. Astri Therapeutics recorded a loss per share of 33.68. The entity had not issued any dividends in recent years. Astria Therapeutics, Inc., a biopharmaceutical company, engages in developing therapies for rare and niche allergic, and immunological diseases in the United States. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. Astri Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. For more info on Astri Therapeutics please contact the company at 617 349 1971 or go to

Astri Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Astri Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Astri Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Astri Therapeutics generated a negative expected return over the last 90 days
Astri Therapeutics has high historical volatility and very poor performance
Astri Therapeutics was previously known as Catabasis Pharmaceuticals and was traded on NGM Exchange under the symbol CATB.
Net Loss for the year was (218.84 M).
Astri Therapeutics currently holds about 131.78 M in cash with (31.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.13, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Astri Therapeutics has a very weak financial position based on the latest SEC disclosures
Roughly 59.0% of the company shares are held by institutions such as insurance companies

Astri Therapeutics Upcoming and Recent Events

Earnings reports are used by Astri Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Astri Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Astri Largest EPS Surprises

Earnings surprises can significantly impact Astri Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Astri Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Astri Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Astri Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Astri Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
6th of January 2022
Unclassified Corporate Event
15th of December 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
22nd of September 2021
Unclassified Corporate Event. Unclassified Corporate Event
8th of September 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
20th of August 2021
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Material Modifications to Rights of Security Holders
9th of July 2021
Unclassified Corporate Event
30th of June 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement

Astri Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Astri Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Astri Therapeutics backward and forwards among themselves. Astri Therapeutics' institutional investor refers to the entity that pools money to purchase Astri Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Perceptive Advisors LlcCommon SharesM17.3 M
Ra Capital Management LpCommon Shares1.3 M11.2 M
Fairmount Funds Management LlcCommon Shares911.7 K8.1 M
Vanguard Group IncCommon Shares553.9 K4.9 M
Cormorant Asset Management LpCommon Shares552.9 K4.9 M
Vr Adviser LlcCommon Shares539 K4.8 M
Citadel Advisors LlcCommon Shares310.6 K2.7 M
Susquehanna International Group LlpPut Options40 K354 K
Note, although Astri Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Astri Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 62.84 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Astri Therapeutics's market, we take the total number of its shares issued and multiply it by Astri Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Astri Profitablity

Astri Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Astri Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Astri Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Astri Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Astri Therapeutics' profitability requires more research than a typical breakdown of Astri Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.78) (0.84) 
Return on Average Equity(0.69) (0.74) 
Return on Invested Capital(2.26) (2.32) 
Return on Sales(48.42) (52.24) 

Management Efficiency

The entity has return on total asset (ROA) of (19.03) % which means that it has lost $19.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (216.31) %, meaning that it created substantial loss on money invested by shareholders. Astri Therapeutics management efficiency ratios could be used to measure how well astri therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/23/2022, Return on Average Assets is likely to drop to -0.84. In addition to that, Return on Average Equity is likely to drop to -0.74. As of 01/23/2022, Tangible Assets Book Value per Share is likely to grow to 14.33, while Total Assets are likely to drop slightly above 50.3 M.
Last ReportedProjected for 2022
Book Value per Share 15.29  16.50 
Enterprise Value over EBIT(1.80) (1.94) 
Enterprise Value over EBITDA 0.27  0.29 
Price to Book Value 0.95  1.31 
Tangible Assets Book Value per Share 13.96  14.33 
Enterprise Value-7.8 M-8 M
Tangible Asset Value54.6 M50.3 M

Technical Drivers

As of the 23rd of January, Astri Therapeutics shows the mean deviation of 3.58, and Risk Adjusted Performance of (0.048894). Astri Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Astri Therapeutics, which can be compared to its rivals. Please confirm Astri Therapeutics variance and potential upside to decide if Astri Therapeutics is priced correctly, providing market reflects its regular price of 4.89 per share. Given that Astri Therapeutics has jensen alpha of (0.35), we suggest you to validate Astri Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Astri Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Astri Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Astri Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Astri Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Astri Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Astri Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Astri Therapeutics Predictive Daily Indicators

Astri Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Astri Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Astri Therapeutics Forecast Models

Astri Therapeutics time-series forecasting models is one of many Astri Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Astri Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Astri Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Astri Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Astri shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Astri Therapeutics. By using and applying Astri Stock analysis, traders can create a robust methodology for identifying Astri entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(47.88) (51.66) 
Gross Margin 0.90  0.89 
Profit Margin(49.26) (53.15) 
Astria Therapeutics, Inc., a biopharmaceutical company, engages in developing therapies for rare and niche allergic, and immunological diseases in the United States. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. Astri Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.

Current Astri Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Astri analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Astri analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
22.8Strong Buy5Odds
Astri Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Astri analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Astri stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Astri Therapeutics, talking to its executives and customers, or listening to Astri conference calls.
Astri Analyst Advice Details

Astri Stock Analysis Indicators

Astri Therapeutics stock analysis indicators help investors evaluate how Astri Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Astri Therapeutics shares will generate the highest return on investment. By understating and applying Astri Therapeutics stock analysis, traders can identify Astri Therapeutics position entry and exit signals to maximize returns.
Shares Percent Shares Out0.97%
Quick Ratio28.04
Fifty Two Week Low4.3000
Short Percent Of Float0.99%
Forward Price Earnings-1.85
Float Shares7.33M
Fifty Two Week High47.8200
Shares Short Prior Month205.41k
Average Daily Volume Last 10 Day38.58k
Average Daily Volume In Three Month45.66k
Fifty Day Average5.8281
Two Hundred Day Average9.2534
Please continue to Trending Equities. Note that the Astri Therapeutics information on this page should be used as a complementary analysis to other Astri Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Astri Stock analysis

When running Astri Therapeutics price analysis, check to measure Astri Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astri Therapeutics is operating at the current time. Most of Astri Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astri Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Astri Therapeutics' price. Additionally, you may evaluate how the addition of Astri Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Is Astri Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astri Therapeutics. If investors know Astri will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astri Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Astri Therapeutics is measured differently than its book value, which is the value of Astri that is recorded on the company's balance sheet. Investors also form their own opinion of Astri Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Astri Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astri Therapeutics' market value can be influenced by many factors that don't directly affect Astri Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astri Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Astri Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astri Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.